Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Fibrinogen,Thrombin
Therapeutic Area: Hematology Product Name: TachoSil
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Corza
Deal Size: $407.9 million Upfront Cash: $407.9 million
Deal Type: Divestment September 16, 2020
Details:
Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human fibrinogen,Thrombin
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Termination April 10, 2020
Details:
In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
